- Financial Times stated that the new fast-spreading COVID variant from South Africa is being tested by the BioNTech
- Israel, Hong Kong, Botswana, and South Africa, all of these countries, have been detected with this new variant called B.1.1.529
- Whether the new vaccine works against this virus or not will be known after the next two weeks.
It was mentioned in the Financial Times that the Vaccine For New Covid Variant does not have much testing and research. Against the new variant, whether the vaccination proves to be effective or not will be found out after two weeks as BioNTech has asked for a duration of two weeks to be sure. This new variant that emerged in South Africa is, and the vaccine against it is being developed by Pfizer and BioNTech together.
Israel, Hong Kong, Botswana, and South Africa are all under strict observance by the health minister and the Scientists in order to chalk out important information regarding the new variant B.1.1.529.
It was reported previously that the new variant would not respond to any treatment or vaccination as it is too strong and powerful. The antibody treatments and vaccination are ineffective against it because the spike protein on which Coronavirus attacks accepts about 32 mutations from this variant. So all these mutations are harder to control and fight.
The least amount of time that can be given to researchers is of two weeks to find out more about this new variant through testing and analysis, Stated BioNTech. B.1.1.529 variant is under investigation, and experts seemed too concerned about this new strain of coronavirus.
This variant is way more different than any other variant of coronavirus detected before. It has more mutations and more forms that it can change into, making it more deadly and contagious.
The company stated that the precautionary measures were already being taken, and the escape variant was already under hundred day observation period. Within six weeks, the m RNA vaccine was to be created a month ago. In October, actions regarding it were already being planned by BioNTech and Pfizer together.
The company further mentioned that the regulators could be provided with the data of tolerance and protection from the vaccines for alpha and delta variants. To collect and carry out these numbers and data, clinical trials have begun by the companies.
A person visited Malawi and, on his return, brought the B.1.1.529 variant with himself to Israel. It was reported on Friday that this is how the first case occurred in Israel. The deadly and infectious role of the B.1.1.529 variant is because of the increased mutations or not is still not confirmed. Experts are saying that it could be something else too. It is not necessary that the cause is its thirty-two mutations. After two weeks, hopefully, everything will be figured out by BioNTech and Pfizer.